AU2020334060B2 - Polymorphic forms of deoxycytidine, compositions comprising the same and uses - Google Patents

Polymorphic forms of deoxycytidine, compositions comprising the same and uses Download PDF

Info

Publication number
AU2020334060B2
AU2020334060B2 AU2020334060A AU2020334060A AU2020334060B2 AU 2020334060 B2 AU2020334060 B2 AU 2020334060B2 AU 2020334060 A AU2020334060 A AU 2020334060A AU 2020334060 A AU2020334060 A AU 2020334060A AU 2020334060 B2 AU2020334060 B2 AU 2020334060B2
Authority
AU
Australia
Prior art keywords
ppm
deoxycytidine
composition
residual solvent
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020334060A
Other languages
English (en)
Other versions
AU2020334060A1 (en
Inventor
Paul Glidden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biosciences Inc
Original Assignee
UCB Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biosciences Inc filed Critical UCB Biosciences Inc
Publication of AU2020334060A1 publication Critical patent/AU2020334060A1/en
Assigned to ZOGENIX MDS, INC. reassignment ZOGENIX MDS, INC. Amend patent request/document other than specification (104) Assignors: MODIS THERAPEUTICS INC.
Assigned to ZOGENIX, INC. reassignment ZOGENIX, INC. Request for Assignment Assignors: ZOGENIX MDS, INC.
Assigned to UCB BIOSCIENCES, INC. reassignment UCB BIOSCIENCES, INC. Request for Assignment Assignors: ZOGENIX, INC.
Application granted granted Critical
Publication of AU2020334060B2 publication Critical patent/AU2020334060B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AU2020334060A 2019-08-19 2020-08-19 Polymorphic forms of deoxycytidine, compositions comprising the same and uses Active AU2020334060B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962888893P 2019-08-19 2019-08-19
US62/888,893 2019-08-19
PCT/US2020/047047 WO2021034962A1 (en) 2019-08-19 2020-08-19 Polymorphic forms of deoxycytidine, compositions comprising the same and uses

Publications (2)

Publication Number Publication Date
AU2020334060A1 AU2020334060A1 (en) 2022-03-24
AU2020334060B2 true AU2020334060B2 (en) 2024-11-14

Family

ID=74647126

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020334060A Active AU2020334060B2 (en) 2019-08-19 2020-08-19 Polymorphic forms of deoxycytidine, compositions comprising the same and uses

Country Status (8)

Country Link
US (1) US11649259B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017502A4 (cg-RX-API-DMAC7.html)
JP (2) JP7769603B2 (cg-RX-API-DMAC7.html)
CN (1) CN114929240B (cg-RX-API-DMAC7.html)
AU (1) AU2020334060B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022002513A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150755A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021034962A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022204555A1 (en) * 2021-03-26 2022-09-29 Zogenix Mds, Inc. Aqueous solutions containing purines and pyrimidines and uses thereof
WO2026082601A2 (en) * 2024-10-15 2026-04-23 UCB Biopharma SRL Method of purification

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898936A (en) * 1984-09-24 1990-02-06 Pcr, Inc. 2-deoxyuridines and riboside precursors
JPS61135597A (ja) * 1984-12-06 1986-06-23 Takeda Chem Ind Ltd シチジンおよびデオキシシチジンの製造法
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
JP2002255991A (ja) * 2000-12-27 2002-09-11 Mitsui Chemicals Inc 保護化2’−デオキシシチジン誘導体の製造法
JP2002293791A (ja) * 2001-03-30 2002-10-09 Mitsui Chemicals Inc 保護化2’−デオキシシチジン誘導体の精製法
CN100424091C (zh) * 2002-06-05 2008-10-08 三井化学株式会社 保护化2’-脱氧胞苷类的精制法
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US9669048B2 (en) * 2012-10-25 2017-06-06 Fresenius Kabi Oncology Limited Stable pharmaceutical composition of 5-aza-2′-deoxycitidine
WO2016205671A1 (en) 2015-06-17 2016-12-22 The Trustees Of Columbia University In The City Of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
GB2580963C (en) * 2019-02-01 2025-09-03 Hemispherian As Cancer therapies

Also Published As

Publication number Publication date
JP7769603B2 (ja) 2025-11-13
AU2020334060A1 (en) 2022-03-24
US20210054014A1 (en) 2021-02-25
EP4017502A4 (en) 2023-11-01
CN114929240A (zh) 2022-08-19
JP2025160233A (ja) 2025-10-22
EP4017502A1 (en) 2022-06-29
CA3150755A1 (en) 2021-02-25
CN114929240B (zh) 2024-10-29
JP2022544831A (ja) 2022-10-21
US11649259B2 (en) 2023-05-16
BR112022002513A2 (pt) 2022-05-03
WO2021034962A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
CN110636884B (zh) 新结晶形式
RU2414470C2 (ru) Кристаллические формы соединения тиазолидиндиона и способ его получения
JP2025160233A (ja) デオキシシチジンの多形形態、それを含む組成物および使用
US20220389011A1 (en) Crystalline form of tolebrutinib and preparation method thereof
TW201136593A (en) Nucleoside phosphoramidates
US12297224B2 (en) Crystal form, preparation method, and application of 4'-substituted nucleoside
KR102788829B1 (ko) 야누스 키나제 억제제의 결정질 형태
CN116745292A (zh) 经取代的吡啶并三嗪化合物及其用途
AU2012228439C1 (en) Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (SYK)
EP3650448A1 (en) Indole-formamide derivative, preparation method therefor and use thereof in medicine
WO2014145600A1 (en) Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
KR102566383B1 (ko) 3-하이드록시-비스-벤질옥시-6-벤질옥시메틸-2-페닐-2-옥소-2λ5-[1,2]옥사포스피난의 결정질 다형 형태
WO2022247885A9 (zh) 三并杂环类化合物的结晶和盐及其应用
US20230192622A1 (en) Anti-sars-cov-2 drug
CN118005694B (zh) 一种环状核苷类似物及其制备方法和应用
US20260091039A1 (en) Hydrochloric acid salt of a 5-ht2c agonist
CN113666895B (zh) 卤代2-苯并[c]呋喃酮类化合物及其应用
WO2023105483A1 (en) Crystalline forms of a 5-aminopyrazole compound useful for treating hbv
CN116829153A (zh) 治疗流感化合物的晶型及应用
CN103237804B (zh) 制备纳曲酮的方法
KR20210155806A (ko) Pi3k 저해제의 결정다형 및 이의 제조방법
WO2002004474A1 (en) Adenosine compound and pharmaceutical composition containing the same
HK40016048B (en) Novel crystalline forms

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ZOGENIX MDS, INC.

Free format text: FORMER NAME(S): MODIS THERAPEUTICS INC.

PC1 Assignment before grant (sect. 113)

Owner name: ZOGENIX, INC.

Free format text: FORMER APPLICANT(S): ZOGENIX MDS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: UCB BIOSCIENCES, INC.

Free format text: FORMER APPLICANT(S): ZOGENIX, INC.

FGA Letters patent sealed or granted (standard patent)